OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial

Abstract

Background:

We examined the blood conserving effect of tranexamic acid in total hip arthroplasty using the direct anterior approach with enoxaparin as deep vein thrombosis (DVT) chemoprophylaxis, and whether this translates to an effect on functional outcomes in the perioperative period. We also compare the effect of aspirin and enoxaparin as DVT chemoprophylactic agents.

Methods:

We conducted a single-centre randomised, double-blinded, placebo-controlled trial. 105 patients were randomised to receive either tranexamic acid or an equivalent volume of normal saline with enoxaparin used as DVT chemoprophylaxis. The primary outcome measure was thigh swelling. Blood loss and the incidence of blood transfusions was also recorded. Secondary outcome measures including postoperative functional scores and mobility, pain scores and length of stay. We also compared and pooled the results of a previous study with the same study intervention methodology which used aspirin as DVT chemoprophylaxis instead of enoxaparin.

Results:

There were no statistically significant differences between the primary outcome of thigh swelling. There was significantly less intraoperative blood loss observed in the tranexamic acid (TXA) group (0.510 L, SD 0.210) compared with the control group (0.698, SD 0.301) (p < 0.001). The estimated blood loss was also significantly less in the TXA group (1.130 L, SD 0.311) compared with the control group (1.48 L, SD 0.510) (p < 0.001). Pooled data of both consecutive trials showed there was a statistically significant reduction in length of stay for those that received TXA (3.72 days, SD 0.83 versus 4.24 days, SD 0.97, p < 0.001). There was also a statistically significant increased risk of a transfusion in the control group as compared those that received TXA (OR 5.5, 1.188 to 25.449, p = 0.029). There was no difference in blood loss between DVT chemoprophylactic agents.

Interpretation:

TXA is an effective agent in reducing blood loss in THR using the anterior approach and was not affected by choice of DVT chemoprophylaxis. Patients who received TXA had fewer transfusions and a reduction in their length of stay. The blood conserving effect of TXA was not associated with improved postoperative recovery across the measures of pain and mobility.

Clinical trials registration:

ANZCTR number: ACTRN12616000606482.

Keywords

Anterior approach aspirin DVT chemoprophylaxis enoxaparin total hip replacement tranexamic acid

Get full access to this article

View all access options for this article.

References

Sukeik

Alshryda

Haddad

et al . Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 2011; 93: 39–46.

Henry

Carless

Moxey

et al . Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011; (1): CD001886.

Fraval

Effeney

Fiddelaers et al . OBTAIN A: outcome benefits of tranexamic acid in hip arthroplasty. A randomized double-blinded controlled trial. J Arthroplasty 2017; 32: 1516–1519.

Dunn

Goa

. Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999; 57: 1005–1032.

Sharfman

Campbell

Mirocha

et al . Balancing thromboprophylaxis and bleeding in total joint arthroplasty: impact of eliminating enoxaparin and predonation and implementing pneumatic compression and tranexamic acid. J Arthroplasty 2016; 31: 1307–1312.

Johansson

Pettersson

Lisander

. Tranexamic acid in total hip arthroplasty saves blood and money: a randomized, double-blind study in 100 patients. Acta Orthop 2005; 76: 314–319.

Imai

Dohmae

Suda

et al . Tranexamic acid for reduction of blood loss during total hip arthroplasty. J Arthroplasty 2012; 27: 1838–1843.

Stranden

. A comparison between surface measurements and water displacement volumetry for the quantification of leg edema. J Oslo City Hosp 1981; 31: 153–155.

Gordon

Stevenson

Griffie

et al . Opioid equianalgesic calculations. J Palliat Med 1999; 2: 209–218.

10.

Gross

. Estimating allowable blood loss: corrected for dilution. Anesthesiology 1983; 58: 277–280.

11.

Nadler

Hidalgo

Bloch

. Prediction of blood volume in normal human adults. Surgery 1962; 51: 224–232.

12.

Benoni

Fredin

Knebel

et al . Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations. Acta Orthop Scand 2001; 72: 442–448.

13.

Niskanen

Korkala

. Tranexamic acid reduces blood loss in cemented hip arthroplasty: a randomized, double-blind study of 39 patients with osteoarthritis. Acta Orthop 2005; 76: 829–832.

14.

Singh

Ballal

Mitchell

et al . Effects of tranexamic acid on blood loss during total hip arthroplasty. J Orthop Surg (Hong Kong) 2010; 18: 282–286.

15.

Garneti

Field

. Bone bleeding during total hip arthroplasty after administration of tranexamic acid. J Arthroplasty 2004; 19: 488–492.